QUILT-505 trial: what clinicians have said so far
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- NCT06239220 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on QUILT-505 (PD-L1 t-haNK plus NAI plus cetuximab in immunotherapy-treated recurrent metastatic HNSCC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on QUILT-505 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- PD-L1 t-haNK; Cetuximab; NAI
- Arms
- Dose Level 0: PD-L1 t-haNK + NAI + Cetuximab · Experimental
- Dose Level -1: PD-L1 t-haNK + NAI + Cetuximab · Experimental
- Enrollment
- 25 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Dana-Farber Cancer Institute with ImmunityBio, Inc.
- Start
- Feb 16, 2024
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06239220 · updated Oct 19, 2026